Agios Interest Income from 2010 to 2024

AGIO Stock  USD 55.54  0.92  1.68%   
Agios Pharm Interest Income yearly trend continues to be very stable with very little volatility. Interest Income is likely to grow to about 35 M this year. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals
 
Interest Income  
First Reported
2019-03-31
Previous Quarter
8.1 M
Current Value
13.1 M
Quarterly Volatility
3.7 M
 
Covid
Check Agios Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharm's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 M, Interest Expense of 15.4 M or Selling General Administrative of 81.2 M, as well as many indicators such as Price To Sales Ratio of 32.17, Dividend Yield of 0.0 or PTB Ratio of 1.45. Agios financial statements analysis is a perfect complement when working with Agios Pharm Valuation or Volatility modules.
  
Check out the analysis of Agios Pharm Correlation against competitors.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Latest Agios Pharm's Interest Income Growth Pattern

Below is the plot of the Interest Income of Agios Pharm over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Agios Pharm's Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Agios Pharm's overall financial position and show how it may be relating to other accounts over time.
Interest Income10 Years Trend
Slightly volatile
   Interest Income   
       Timeline  

Agios Interest Income Regression Statistics

Arithmetic Mean8,956,880
Geometric Mean3,634,998
Coefficient Of Variation129.49
Mean Deviation9,023,440
Median2,514,000
Standard Deviation11,598,080
Sample Variance134.5T
Range34.2M
R-Value0.76
Mean Square Error61.8T
R-Squared0.57
Significance0
Slope1,963,598
Total Sum of Squares1883.2T

Agios Interest Income History

202435 M
202333.3 M
202212.8 M
2021836 K
20206.6 M
201914.9 M
201816.5 M

Other Fundumenentals of Agios Pharm

Agios Pharm Interest Income component correlations

0.97-0.090.03-0.470.710.980.330.980.020.90.80.910.260.92-0.140.770.860.880.75-0.15
0.97-0.170.06-0.270.590.960.070.95-0.070.840.670.960.090.85-0.220.790.930.90.71-0.16
-0.09-0.17-0.8-0.020.36-0.070.24-0.060.96-0.040.16-0.220.0-0.20.92-0.03-0.33-0.39-0.480.22
0.030.06-0.80.05-0.350.01-0.090.02-0.710.0-0.210.13-0.040.13-0.58-0.140.20.290.52-0.26
-0.47-0.27-0.020.05-0.67-0.45-0.82-0.44-0.12-0.68-0.76-0.25-0.73-0.680.04-0.21-0.1-0.24-0.470.18
0.710.590.36-0.35-0.670.660.560.650.410.780.870.460.530.650.270.610.360.350.37-0.01
0.980.96-0.070.01-0.450.660.260.990.060.920.80.950.250.93-0.130.670.830.870.74-0.23
0.330.070.24-0.09-0.820.560.260.320.340.430.630.010.670.440.290.08-0.060.10.310.01
0.980.95-0.060.02-0.440.650.990.320.080.890.810.930.230.92-0.080.660.850.890.76-0.22
0.02-0.070.96-0.71-0.120.410.060.340.080.070.27-0.09-0.04-0.040.92-0.07-0.2-0.22-0.26-0.01
0.90.84-0.040.0-0.680.780.920.430.890.070.880.80.450.93-0.10.610.650.720.71-0.21
0.80.670.16-0.21-0.760.870.80.630.810.270.880.630.560.830.140.460.470.550.58-0.14
0.910.96-0.220.13-0.250.460.950.010.93-0.090.80.630.00.88-0.250.630.910.920.75-0.29
0.260.090.0-0.04-0.730.530.250.670.23-0.040.450.560.00.33-0.120.17-0.17-0.040.110.22
0.920.85-0.20.13-0.680.650.930.440.92-0.040.930.830.880.33-0.220.580.750.830.83-0.3
-0.14-0.220.92-0.580.040.27-0.130.29-0.080.92-0.10.14-0.25-0.12-0.22-0.18-0.33-0.36-0.360.16
0.770.79-0.03-0.14-0.210.610.670.080.66-0.070.610.460.630.170.58-0.180.680.560.310.3
0.860.93-0.330.2-0.10.360.83-0.060.85-0.20.650.470.91-0.170.75-0.330.680.960.76-0.31
0.880.9-0.390.29-0.240.350.870.10.89-0.220.720.550.92-0.040.83-0.360.560.960.87-0.39
0.750.71-0.480.52-0.470.370.740.310.76-0.260.710.580.750.110.83-0.360.310.760.87-0.61
-0.15-0.160.22-0.260.18-0.01-0.230.01-0.22-0.01-0.21-0.14-0.290.22-0.30.160.3-0.31-0.39-0.61
Click cells to compare fundamentals

About Agios Pharm Financial Statements

Agios Pharm investors utilize fundamental indicators, such as Interest Income, to predict how Agios Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Interest Income33.3 M35 M
Net Interest Income33.3 M35 M

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving against Agios Stock

  0.85TCHH Trustcash HoldingsPairCorr
  0.76PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr
  0.7JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.61ME 23Andme HoldingPairCorr
  0.6MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out the analysis of Agios Pharm Correlation against competitors.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
11.66
Revenue Per Share
0.582
Quarterly Revenue Growth
0.212
Return On Assets
(0.18)
Return On Equity
0.5366
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.